Gregory Sampognaro, MD
Interventional Cardiology · Monroe, LANPI 1467546168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 804 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,677, 2.9 times the $1,623 reported in 2019.
Across 804 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$2K
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Abiomed$967
- Johnson & Johnson$924
- plus $8K from 40 others
Across 17 payments — averaging $1461.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$18K
- Abbott$3K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Travel & lodging$1,4518%
- Food & beverage$16,89392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,437
- Torus Stent Graft System$504
- ENDOCROSS Device$504
- Impella$219
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$130
- SYMPLICITY G3$129
- ADVISOR$128
- MYNX CONTROL VENOUS$123
- Quadra Assura CRT Defibrillator$117
- WatchPATONE$117
- Assurity Pacemaker$114
- XARELTO$114
- Barostim Neo System$112
- ASSURITY$108
- Trilogy 100$107
- NEXLIZET$104
- NEXLETOL$104
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$102
- Edwards SAPIEN 3 Transcatheter Heart Valve$100
How this compares
$18,344 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 725 | $493,153 |
| EntrestoSacubitril/Valsartan | 150 | $119,573 |
| MultaqDronedarone Hcl | 119 | $111,831 |
| XareltoRivaroxaban | 45 | $38,340 |
| Metoprolol Succinate | 587 | $8,419 |
| Repatha SureclickEvolocumab | 15 | $7,887 |
| Nifedipine ErNifedipine | 435 | $7,770 |
| Ranolazine ErRanolazine | 131 | $7,114 |
| BrilintaTicagrelor | 11 | $6,769 |
| Clonidine | 65 | $6,586 |
| Dofetilide | 17 | $4,813 |
| Ezetimibe | 198 | $4,545 |
| ClopidogrelClopidogrel Bisulfate | 446 | $4,488 |
| Losartan Potassium | 339 | $4,332 |
| Flecainide Acetate | 122 | $4,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $670 | $493,153725 claims |
| NovartisEntresto | $1,405 | $119,573150 claims |
| Sanofi-aventis U.S. LLCMultaq | $269 | $111,831119 claims |
| Johnson & JohnsonXarelto | $924 | $38,34045 claims |
| AstraZenecaBrilinta | $27 | $6,76911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Monroe
- Nauman KhalidMonroe$31K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
- Pradeep NairHouma$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.